Yasutaka Nishijima

signpost Corp. engages in the provision of genetic test programs and solutions against lifestyle diseases. It develops genetic test programs including signpost exercise and nutrition guidance program and signpost metabolic syndrome and diabetes mellitus risk analysis. The company was founded on September 1, 2004 and is headquartered in Osaka, Japan.

SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA.